To Fix Alert Fatigue in Healthcare, Focus on These 3 Things

Explore the evolution and current challenges in clinical decision-making for prescription management, and how AI is shaping the future of healthcare practices.

AI is transforming the healthcare industry. Most importantly, AI is helping personalize patient care in impactful ways.

Explore PHYDGI, a database for consistent herb-drug interaction (HDI) risk assessment. Bridging gaps in HDI knowledge for healthcare professionals.

Explore how AI is revolutionizing drug monitoring by automating pharmacovigilance, enhancing patient safety, and streamlining adverse event reporting.

Explore how our Drug Data Import component optimizes patient treatment transcription, saving time, and reducing errors.

In this article, we will explore the advantages of drug databases, their use cases, the challenges of building and integrating them.

As a pharmacy extern, I have been fortunate enough to work on the COVERAGE clinical trial promoted by Bordeaux University Hospitals and led by principal investigator Professor Denis Malvy, infectious disease expert and head of the tropical diseases unit at Bordeaux University Hospital, member of the IDLIC research team for “Infectious diseases in countries with limited resources” led by Doctor Xavier Anglaret at the Bordeaux Population Health Research Centre (Inserm and Bordeaux University).

The COVID-19 pandemic has been playing an important role in the large adoption of telemedicine around the world. According to a recent study from McKinsey, 46% of consumers in the U.S were using telemedicine in June 2020, while they were 11% a year earlier. However, the growth of teleconsultations can increase the risk of inadequate use of medication which can lead to hospitalizations and deaths. Hence, it is crucial for telemedicine platforms to secure their prescriptions.

Several Synapse Medicine employees contributed to this article, which will revisit many of the great projects the company worked on throughout 2020. We’re also taking advantage of this occasion to share our goals and vision for 2021 with you.

July 6, 2020 – Synapse Medicine has announced that it has raised 8 million dollars, spearheaded by the MACSF, a leading insurance provider for healthcare professionals, and with the support of XAnge, BNP Paribas, BPI, and Nicolas Dessaigne, co-founder of Algolia. The purpose of this move is to continue the development of its leading-edge medication intelligence platform, which is already being used by thousands of healthcare professionals and patients daily. The company has now raised 11 million dollars over a 14-month period and tripled the size of its staff.

The Medication Shield technology, which was developed thanks to a partnership between public and private sector, provides considerable help for pharmacovigilance experts in analyzing adverse drug reaction (ADR) reports. In this article, Dr. Clement Goehrs, Co-Founder and CEO of Synapse Medicine, reveals how the project was developed.

It is crucial for telemedicine platforms to ensure the safety of all telehealth consultations and to improve the user experience of physicians when writing prescriptions. In this case study, you will discover how Medication Intelligence ensures the safety of Hellocare’s telehealth consultations while facilitating real time decision-making by its prescribers.

In this interview, Marie-Laure Saillard, CEO of MesDocteurs, and Dr. Clément Goehrs, co-founder and CEO of Synapse Medicine, reflect back on how telemedicine evolved in 2020.

At exactly 11:38 a.m. on Saturday 14 March, French Health Minister Olivier Véran tweeted the following message: “#COVID-19 | Taking anti-inflammatory drugs (ibuprofen, cortisone…) could worsen the infection. If you develop a fever, take paracetamol. If you are already on anti-inflammatory drugs, or if in doubt, please consult with your doctor.”

Since the beginning of the Covid-19 health crisis, our teams at Synapse Medicine have been hard at work developing technological solutions for both medical professionals and the general public. We have featured our different initiatives related to the novel coronavirus on covid19.synapse-medicine.com.

Telemedicine is broadly perceived as a solution that facilitates patient care. Today more than ever, people are looking for useful and accessible digital solutions to help them manage their health. Today more than ever, having experienced life in lockdown, people are looking for useful and accessible digital solutions to help them manage their health.

Alert fatigue isn’t inevitable. Here are three principles industry leaders are using to build better medication alerts and other clinical notifications.

Synapse Medicine, the leader in medication success, and CompuGroup Medical, the leader in software for providers, have announced a partnership to accelerate innovation in prescribing and allow physicians to benefit from time-saving technological advances in clinical decision support.

Synapse Medicine, the leading Medication Intelligence technology, announces a partnership on medication reconciliation with Dedalus, the leading Electronic Health Record (EHR) provider in Europe.

Synapse Medicine has raised $28 million, led by leading European venture firm Korelya Capital, and past investors (XAnge, MACSF, and BNP Paribas Development). This is the third fundraising round in three years for the startup,  reaching a total of $40 million.

Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM). This technology comes out as a valuable time-saver, supporting the management of adverse drug reaction (ADR) reports by making it easier and allowing pharmacovigilance teams to focus their attention on the most severe cases. Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.

France’s Gustave Roussy Institute, Europe's leading cancer center and ranked third in the world according to Newsweek Magazine, has chosen to partner with Synapse Medicine, a leader in clinical pharmacy and medication reconciliation.

Synapse Medicine has announced that it has raised 8 million dollars, spearheaded by the MACSF, a leading insurance provider for healthcare professionals, and with the support of XAnge, BNP Paribas, BPI, and Nicolas Dessaigne, co-founder of Algolia. The purpose of this move is to continue the development of its leading-edge medication intelligence platform, which is already being used by thousands of healthcare professionals and patients daily. The company has now raised 11 million dollars over a 14-month period and tripled the size of its staff.

Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient’s clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency.